Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ershiwuwei Shanhua Wan, also known as the Twenty-Five-Flavor Coral Pill, is a traditional Tibetan medicine (TTM) formulation widely utilized for the treatment of neurological and cerebrovascular disorders. It is composed of 25 distinct ingredients, including precious minerals like coral and pearl, and botanical components such as saffron and musk. The formulation is primarily indicated for cerebral infarction (stroke), hypertension, epilepsy, and various forms of headache or neuritis. Pharmacologically, it is thought to exert neuroprotective effects by improving cerebral microcirculation, reducing oxidative stress, and inhibiting neuronal apoptosis. In the context of Tibetan medicine, it is used to clear heat and tranquilize the mind, specifically targeting rLung (wind) imbalances that affect the nervous system. The drug is manufactured by several prominent Tibetan pharmaceutical companies and has been the subject of clinical research at institutions such as The Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ershiwuwei Shanhua Wan.